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Summary: A method is described for the determination of plasma and serum glycosaminoglycans, which can
be used in any laboratory equipped with an HPLC system. It is based on the sequential application of
chondroitinases AC and ABC and separation of the resulting disaccharides by high-performance liquid
chromatography. All reagents are commercially available. This simple and rapid separation yields an accurate
quantification and an exact distribution pattern. The determination of glycosaminoglycan disaccharides is
linear between 7 and 7000 μιηοΐ/ΐ with coefficients of variation between 3.0 and 7.7% for serum and between
2 and 14% for plasma. The recovery of the assay ranged from 93 to 106% for different concentrations of
glycosaminoglycan disaccharides. This HPLC method may therefore be considered as a candidate reference
method.
Introduction Materials and Methods
Glycosaminoglycans, which are widely distributed in Reagents
human tissues and fluids (1), are intimately related to Chondroitinase AC (EC 4.2.2.5)1) of Anhrobacter aurescens
proteoglycan metabolism. In plasma, glycosamino- Ο01 Ε88301) and chondroitinase ABC (EC 4.2.2.4) of Proteus
. , . - /. , i ι vulgar is (lot E88301) were purchased from Seikagaku Kogyo
glycans have a wide range of molecular masses, but
 (T(fky0j Japan) a.Mannosidase (EC 3.2.1.24) of Canavalia en-
a large proportion have relative molecular masses of siformis Got 48F-9545) was from Sigma (St. Louis, USA) and
less than 5000 (2). Various laboratories have demon- PaP*in <E£ 3.4.22.2) from Carica papayat (lot 12385425-75/May
x ^ , Al ~" - . 1 92) from Boehrmger Mannheim (Mannheim, Germany),
strated the presence of glycosaminoglycans in human
plasma or serum (2-5). The results indicate that a Calibrator disaccharides
great quantitative variability may exist among differ- 2-acetamido-2-deoxy-3-O-( -jD-gluco-4-enepyranosyluronic
ent methods for determination of blood glycosami- acid)-D-ga!actose (Δ DiOS),
noglycans. 2-acetamido-2-deoxy-3-O-( -D-gluco-4-enepyranosyluronic
_ , j t ι - ι j. acid)-4-O-sulpho-Z>-galactose ( Δ Di4S),
Recently we measured the glycosaminoglycan disac-
charides from human blood donors, using two differ- 2-acetamido-2-deoxy-3-O-( -Z)-gluco;4-enepyranosyluronic
, , ' Γ . .
 c . . . . acid)-6-O-sulpho-Z>-galactose (Δ Di6S) and
ent methods for isolation of glycosaminoglycans in
plasma and serum. The Chromatographie conditions
are identical for both methods of glycosaminoglycan
isolation. l) Enzymes:
Significant sex differences in glycosaminog^can di- §£!Α£ igc^g
saccharide composition were found in the present oc-Mannosidase (EC 3.2.1.24)
Study. Papain (EC 3.4.22.2)
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2-acetamido-2-deoxy-3-O-( -JD-gluco-4-enepyranosyl uronic
acid)-£-glucose (Δ DiHA)
were available from Seikagaku Kogyo (Tokyo, Japan).
DEAE-Sephacel was from Pharmacia (Freiburg, Germany). All
other chemicals were of analytical grade (E. Merck, Darmstadt,
Germany).
HPLC equ ipment
Separation and measurements were performed with a Jasco
flow pump Model 880-PU (Techlab, Erkerode, Germany), a
spectrophotometer SP-4 (Gynkotek, Gering, Germany), an au-
tosampler WISP™ Model 710B (Millipore, K nigstein, Ger-
many) and a Philips CM 9043 AT Computer (Philips, Hamburg,
Germany) with an Axiom 717 chroraatography data system
(LDC Analytical, Hasselroth, Germany). A Nucleosil SB 5 an-
ion exhange column (4.6 χ 125 mm, 5 μιη particles) connected
with a Hypersil ODS RP-C 18 reversed phase column (4.6
χ 125 mm, 5 μπι particles) was used to separate sulphated
glycosaminoglycan disaccharides, and a Hypersil APS weak
anion exchange column (4.6 χ 250 mm, 5 μπι particles) con-
nected with a Hypersil ODS RP-C18 column (4.6 χ 15 mm,
5 μιη particles) was used to separate non-sulphated glycosa-
minoglycan disaccharides. Columns were from Shandon/VDS
(Optilab Chromat. Technic, Techlab, Erkerode, Germany). De-
tection was by UV absorbance at 232 nm.
Chromatographie conditions
A filtered (0.4 μπι, Millipore, Neu-Isenburg, Germany) and
helium-saturated mobile phase of 0.22 mol/1 sodium chloride
was used for separation of sulphated disaccharides. The flow
rate was 0.8 ml/min. Non-sulphated components were separated
with the same flow rate by the use of a filtered and oxygen-
poor mobile phase of 2.5 mmol/1 disodium hydrogen phosphate,
pH 3.0 containing 15 mmol/1 sodium chloride.
Disaccharides were injected in quantities of 0.07 to 70 nmol
dissolved in ΙΟ μΙ water (7 — 7000 μπιοΐ/ΐ). Solutions of com-
mercially available calibrators were used for quantification (ex-
ternal calibrator method).
Sample preparat ion
Plasma samples were obtained from about 10 ml of whole blood
which were collected in a Monovette® (Sarstedt, Numbrecht,
Germany) tube containing 0.05 mmol/1 EDTA, then centrifuged
at 3000 min'1 (2000g) for 10 minutes at 4°C.
Serum samples were collected in Monovette® (Sarstedt, Num-
brecht, Germany) tubes containing Kaolin. After clotting for
!/2 to 1 hour at room temperature, samples wer centrifuged
under the same conditions. Specimens were stored at 4 °C for
analysis within one day. At -20 °C specimens could be stored
for several months.
Serum supernatants were digested for 16 hours at 60 °C with
300 μΐ papain solution (3 MU/1 cysteine buffer) in 10 ml glass
tubes containing 4.5 ml cysteine buffer (0.011 mol/1 cysteine,
0.045 mol/1 disodium EDTA, 0.045 mol/1 potassium dihydrogen
phosphate, 0.067 mol/1 dipotassium hydrogen phosphate, pH
5.8). Papain (150 μΐ containing 3 MU/1 buffer) and cysteine
(0.05 raol) were then added and digestion continued for a
further 4 h. The cholesterol ester content was diminished by
vigorously extracting each sample with 3.0 ml chloroform.
Peptides were precipitated by storage overnight after the ad-
dition of 2 ml trichloroacetic acid (0.61 mol/1). The solutions
were centrifuged (5000 min"1,20 min at 4 °C) and the recovered
supernatants were washed three times with 5ml w-butanol.
Remaining aqueous phases were evaporated for 5 minutes to
remove the n-butanol. One millilitre equilibration buffer (0.15
mol/1 lithium chloride in 0.02 mol/1 Tris/HCl, pH 8.6) was
added and the solution applied to columns (4.0 χ 1.0 cm I. D.)
packed with DEAE-Sephacel. After washing two times with
5 ml equilibration buffer, glycosaminoglycans were eluted with
8.0 ml of 2.0 mol/1 lithium chloride containing 0.02 mol/1 Tris/
HC1, pH 8.6. The eluate was pooled, evaporated to near dry-
ness, and glycosaminoglycans were precipitated overnight after
addition of 5 μΐ of saturated sodium acetate solution and 12 ml
ethanol at 4 °C. The precipitates were centrifuged (5000 min"1,
20 min at 4°C) and dryed. After dissolving in 1.0 ml double
distilled water, the samples were ready for enzymatic digestion.
Plasma samples (5.0 ml) were applied to columns (4.0 χ 1.0
cm I. D.) packed with DEAE-Sephacel and washed with 10 ml
of a solution (0.15 mol/1 sodium chloride in 0.02 mol/1 Tris/
HC1, pH 8.6). The glycosaminoglycans were eluted with 10 ml
of 2.0 mol/1 lithium chloride containing 0.02 mol/1 Tris/HCl,
pH 8.6, desalted and concentrated to 1.0 ml by ultrafiltration
(membrane 1000K, 0.27 ml/min). Buffer (1.0 ml, 0.1 mol/1
trisodium citrate, pH 4.5) and ΙΟ μΙ α-mannosidase (450 U/l
buffer) were added to the concentrates, which were digested for
18 hours at 37 °C. The solutions were centrifuged (17 000 min"1,
30 min at 8 °C) and the supernates again applied to the same
DEAE-Sephacel columns. After washing the columns with 2.5
ml 0.1 mol/l sodium chloride in 0.02 mol/1 Tris/HCl, pH 8.6,
the glycosaminoglycans were eluted with 2.0 ml of 2.0 mol/1
lithium chloride containing 0.02 mol/1 Tris/HCl, pH 8.6. The
eluates were desalted by ultrafiltration (membrane 1000K, 0.16
ml/min) and concentrated to 600—700 μΐ. After adjusting the
volume of each eluate to 1.0 ml by the addition of double
distilled water, the samples were ready for enzymatic digestion.
The aqueous solutions of glycosaminoglycans were analysed by
the uronic acid method of Kosakai & Yosizawa (6), and by the
direct photometric method of Farndale (7) for sulphated gly-
cosaminoglycans, using 1,9-dimethylrnethylene blue.
The method used for sequential digestion of glycosaminogly-
cans with chondroitinase AC and chondroitinase ABC has been
described by Gurr et al. (8). Each enzymatic degradation step
was followed by separation of products from the undigested
glycosaminoglycans by precipating the undigested polysaccha-
rides with ethanol. The digested products, disaccharides of
hyaluronan, non-sulphated chondroitin, chondfoitin sulphate,
non-sulphated dermatan and dermatan sulphate, were concen-
trated to dryness to rotary evaporation and finally dissolved in
200 μΐ double distilled water. Ten microlitres of sample were
injected for the high performance liquid Chromatographie assay.
Specimens
Blood was obtained in the morning from 30 apparently healthy
volunteers and 78 healthy blood donors (53 men and 55 female,
aged 18 to 60 years). All were in good nutritional state; none
took drugs.
Calibration
Solutions of pure disaccharides were used for calibration (ex-
ternal standard method). Losses of sample preparation were
quantified with glycosaminoglycan Cpolysaccharide calibrators
(internal standard method).
All analyses were performed in duplicate.
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Results and Discussion
High performance liquid chromatography of
the disaccharides
Effect of ion exchanger and ionic strength on the elution
patlern
Nucleosil SB is a potent ion exchanger bonded to
silica gel, with a functional quaternary ammonium
group. Aqueous sodium chloride solutions were used
to separate a calibrator solution of the pure sulphated
glycosaminoglycan disaccharides. Good separation of
sulphated disaccharides was obtained in serum sam-
ples, but in plasma samples no satisfactory separation
was achieved. Further separation on a Hypersil ODS
CIS reversed phase column allowed separation of
plasma components and of the disaccharides chon-
droitin-6-sulphate, chondroitin-4-sulphate, dermatan-
6-sulphate, and dermatan-4-sulphate. The best results
were obtained with 0.22 mol/1 sodium chloride solu-
tions and a flow rate of 0.8 ml/min (fig. 1).
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Fig. 1. HPLC chromatograms of glycosaminoglycan disaccha-
rides in human plasma and serum (same chromatograms
but shorter retention times).
Sulphated glycosaminoglycans in front: chondroitin-4-
sulphate (II) and chondroitin-6-sulphate (I) disaccha-
rides.
Non-sulphated glycosaminoglycans (back): hyaluronan
(IV) and chondroitin (III) disaccharides.
Hypersil APS is a weak potent ion exchanger based
on a primary ammonium salt. Buffered sodium phos-
phate solutions (pH 4.5 to 6.0) were used in prelimi-
nary experiments to separate a calibrator solution of
the pure non-sulphated glycosaminoglycan disaccha-
rides and serum samples. With an additional Hypersil
ODS CIS reversed-phase column, plasma samples
were separated satisfactorily. However, plasma solu-
tions showed a double peak for the two anomeric
forms of the hyaluronan disaccharide, both in pure
calibrator solutions and in plasma solutions (for fur-
ther details see Hjerpe et al. 1982). Variation of ionic
strength, concentration of hydrogen ions and addi-
tionally salt concentrations of the eluent were studied.
Chromatography was finally performed with a solu-
tion containing disodium hydrogen phosphate (2.5
mmol/1, pH 3.0) and sodium chloride (15 mmol/1)
with a flow rate of 0.8 ml/min (fig. 1).
Linearity and recovery
In order to determine the range of linearity, chro-
matography was performed using solutions contain-
ing mixtures of the pure disaccharides in concentra-
tions between 7 and 7000 μπιοΐ/ΐ (0.07 and 70 nmol
per injection). A linear increase in the signal accom-
panied the increase in sample concentration for the
glycosaminoglycan disaccharides over the entire range
(fig. 2). Linear regression analyses of the results gave
y = —0.102 + 0.934x with a correlation coefficient
of 0.999 for 2-acetamido-2-deoxy-3-( -£>-gluco-
4-enepyranosyluronic acid)-4-O-sulpho-Z)-galactose
(Δ Di4S);
y = 0.958 + 0.924x with a correlation coefficient
of 0.999 for 2-acetamido-2-deoxy-3-( -D-gluco-
4-enepyranosyluronic acid)-6-O-sulpho-Z)-galactose
(Δ Di6S);
y = 1.138 + 1.054x with a correlation coefficient of
0.999 for 2-acetamido-2-deoxy-3-( -D-gluco-4-ene-
pyranosyluronic acid)-D-galactose (Δ DiOS); and
y = 1.618 + 1.127x with a correlation coefficient of
0.999 for 2-acetamido-2-deoxy-3-( -D-gluco-4-ene-
pyranosyluronic acid)-Z)-glucose (Δ DiHA).
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Fig. 2. Linearity of detector response: peak area vs. sample
concentration.
Hyaluronan (o), chondroitin (o), chondroitin-4-sul-
phate (x), chondroitin-6-sulphate (n) disaccharide.
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Tab. 1. Recovery of glycosarainoglycan disaccharides in different concentrations.
Glycosaminoglycan disaccharide
2-Acetamido-2-deoxy-3-O-( -/)-gluco-4-enepyranosyluronic acid)-
£>-galactose (Δ DiOS)
Expected
concentrations
[μιηοΐ/ΐ]
107
170
229
352
414
436
Recovered
concentration
[μπιοΐ/ΐ] ,
 f
166
243
343
393
434
Relative
difference
[%]
-2.35
+6.11
-2.84
-5.07
-0.46
mean: —0.92
2-Acetamido-2-deoxy-3-O-( -£-gluco-4-enepyranosyluronic acid)-
D-glucose (Δ DiHA)
66.6
203
342
411
475
__
209
331
395
460
+ 2.96
-3.22
-3.89
-3.16
mean: —1.83
2-Acetamido-2-deoxy-3-O-( -D-gluco-4-enepyranosyluronic acid)-
6-O-sulpho-Z)-galactose (Δ Di6S)
18.6
29.6
48.2
89.1
108
28.0
44.9
90.2
109
-5.41
-6.85
+ 1.24
+0.93
mean: -2.52
2-Acetamido-2-deoxy-3-O-( -D-gluco-4-enepyranosyluronic acid)-
4-O-sulpho-Z)-galactose (Δ Di4S)
18.6
27.2
48.9
75.7
103
213
26.4
45.4
74.6
103
211
-2.94
-7,16
-1.45
+0.00
-1.13
mean: -2.54
To investigate the recovery of the method, various
concentrations of pure sulphated and non-sulphated
disaccharides were added to blood samples. Recovery
ranged
from 92.8 to 100% for Δ Di4S,
from 93.1 to 101% for Δ Di6S,
from 96.1 to 103% for Δ DiHA and
from 94.9 to 106% for Δ DiOS (tab. 1, fig. 3).
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Fig. 3. Recovery of chondroitin disaccharide. Chromatograms
of increasing quantities of added calibrator are super-
imposed.
For comparison, glucuronic acid added to blood sam-
ples showed a recovery of 92.3% with the assay of
Kosaki & Yosizawa, while added polymeric chondro-
itin sulphate showed a recovery of 89.5% with the
assay of Farndale et al. These findings imply that the
losses are accounted for in the preparation steps of
plasma/serum and not in the enzymatic digestion
steps.
The sensitivity of the method when defined as a signal
to noise ratio > 3 is at least 3.0 μηιοΐ/ί serum or
plasma (0.1 nmol per injection). This value is in ac-
cordance with other methods (14, 15).
Precision
The total imprecision of the method was determined
for pure calibrators, and for plasma and serum sam-
ples. Coefficients of variation ranging from 1.3 to
2.3% for non-sulphated calibrators (ADiHA and
Δ DiOS) and from 1.5 to 2.1% for sulphated calibra-
tors (Δ Di4S and Δ Di6S) were calculated within a
series of 18 and 20 chromatograms, respectively (con-
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centrations between 67 and 238 μιηοΐ/ΐ; data not
shown). For plasma/serum samples the coefficients of
variation did not exceed 5.4% for sulphated glycos-
aminoglycan disaccharides (n = 14, resp. 20; tab. 2).
For determination of the inter-assay coefficient of
variation replicate chromatograms were run on 7 or
10 consecutive days (tab. 3). The coefficients of var-
iation ranged between 1.1 and 4.7% for non-sul-
phated calibrators, up to 6.8% for sulphated calibra-
tors, up to 7.6% for non-sulphated glycosaminogly-
can disaccharides in plasma/serum samples and be-
tween 7.1 and 17% for sulphated glycosaminoglycan
disaccharides in blood samples. No recalibration was
carried out during these experiments, but the columns
were changed after approximately 150 runs. The high
coefficients of variation within a series for Δ DiHA
and from day to day for Δ Di6S can be explained by
the low concentrations of these disaccharides in
plasma samples. Apart from these exceptions, coef-
ficients of variation do not exceed 7.9%.
The total imprecision of the method, within-run im-
prescision and day-to-day variation are equal to or
less than those reported for other HPLC assays in
plasma/serum (15).
Determination of glycosaminoglycan distri-
bution pattern
For the determination of glycosaminoglycan distri-
bution patterns a technique has been described in
which hyaluronan, chondroitin, chondroitin sulphate,
dermatan and finally dermatan sulphate are digested
in sequential steps using papain/mannosidase, chon-
droitinase AC and chondroitinase ABC, followed by
high performance liquid Chromatographie analysis of
the metabolites. Firstly, interfering plasma/serum
components must be removed by column chromato-
graphy. Up to 30% of serum proteins were bound on
DEAE-Sephacel, but more than 98% of plasma pro-
teins were eluted together with plasma glycosamino-
glycans. Samples were then desalted by ultrafiltration
or precipitated with ethanol. This step was necessary
for accurate and quantitative determination of gly-
cosaminoglycans. Four or five working days were
required to determine the glycosaminoglycans and
their distribution pattern. The proteolysis with pa-
pain/mannosidase was time-consuming but necessary.
After this enzymatic digestion, all glycosaminoglycans
were detected in the supernates, so that blood samples
could easily be processed in a few days and then
analysed overnight.
Tab. 2. Reproducibility of high-performance liquid Chromatographie analysis in plasma and serum. Coefficients of variation
within a series.
Glycosaminoglycan disaccharides
2-Acetamido-2-deoxy-3-O-( -/)-gluco-4-enepyranosyl-
uronic acid)-Z)-glucose (Δ DiHA)
2-Acetamido-2-deoxy-3-O-( -/)-gluco-4-enepyranosyl-
uronic acid)-Z)-galactose (Δ DiOS)
2-Acetamido-2-deoxy-3-O-( -/)-gluco-4-enepyranosyl-
uronic acid)-4-O-sulpho-D-galactose (Δ Di4S)
2-Acetamido-2-deoxy-3-O-( -,D-gluco-4-enepyranosyl-
uronic acid)-6-O-sulpho-jD-galactose (Δ Di6S)
Material
plasma
serum
plasma
serum
plasma
serum
plasma
serum
Number of
measurements
18
20
18
20
14
20
14
20
Concentration
Qimol/1]
7.00 ± 0.98
8.60 ± 0.27
110 +4.05
9.70 ± 0.29
169 ± 4.43
7.90 ± 0.30
5.00 + 0.30
9.32 ± 0.32
Coefficient of
variation [%]
14.0
3.56
3.68
3.03
2.62
4.02
5.38
3.62
Tab. 3. Reproducibility of high-performance liquid Chromatographie analysis in plasma and serum. Coefficients of variation
between the series (from day to day).
Glycosaminoglycan disaccharides
2-Acetamido-2-deoxy-3-O-( -£-gluco-4-enepyranosyl-
uronic acid)-D-glucose (Δ DiHA)
2-Acetamido-2^deoxyr3-O-( ^/)-gluco-4-enepyranosyl-
uronic acid)-D-galactose (Δ DiOS)
2-Aretarnido-2-deoxyr-3-O-( -Z>-gluco-4-enepyranosyl-
uronic acid)-4-O-sulpho-D-galactose (Δ Di4S)
2-Acetamido-2-deoxy-3-O-( -Z)-gluco-4-enepyranosyl·
uronic acidJ-o-O-sulpho-^galactose (Δ Di6S)
Material
plasma
serum
plasma
serum
plasma
serum
plasma
serum
Number of
measurements
7
10
7
10
7
10
7
10
Concentration
[μιηοΐ/ΐ]
7.00 + 0.48
8.62 ± 0.61
110 + 7.30
9.73 ± 0.51
169 + 13.3
7.90 ± 0.56
5.00 ± 0.85
9.32 ± 0.59
Coefficient of
variation [%]
6.86
7.61
6.64
5.06
7.87
7.07
17.0
6.97
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The chondroitin and chondroitin-4-sulphate disaccha-
rides account for up to 92% of the total glycosami-
noglycans in serum; only traces of dermatan-6-sul-
phate and dermatan were detectable (tab. 4). Different
methods (2,3,5,10) yield similar distribution patterns
of disaccharides.
Tab. 4. Glycosaminoglycan disaccharide concentrations, analysed in serum
a) males (n = 53)
Glycosaminoglycan disaccharides [μιηοΐ/ΐ]
Patients
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
Af\49
50
C 451
52
53
χ
s
Hyaluronan
0.39
0.71
0.00
0.08
0.17
1.20
0.50
0.19
0128
0.13
0.00
0.00
0.27
0.51
0.00
0.52
0.00
0.24
0.00
0.00
0.39
0.71
0.00
0.08
0.17
0.50
0.19
0.28
0.13
0.17
0.66
0.55
0.69
0.00
0.06
0.28
0.06
0.00
0.17
0.62
0.00
0.27
0.15
0.05
0.33
0.02
0.25
0.10
0.26
0.49
0.38
0.37
0.39
0.263
0.251
Chondroitin
5.14
4.84
5.63
1.48
4.64
3.05
7.18
5.30
7.09
3.66
4.38
4.25
3.63
1.00
1.98
8.08
5.51
5.20
3.53
8.52
5.14
4.84
5.63
1.48
4.64
7.18
5.30
7.09
3.66
9.19
6.40
2.94
6.46
4.72
3.92
5.71
4.04
3.44
3.56
5.06
1.38
9.97
2.38
4.39
5.66
7.08
11.01
4.05
9.67
3.00
1.89
11.57
3.74
5.10
2.39
Chondroitin-
4-sulphate
0.68
1.15
4.78
1.30
2.46
5.09
0.30
4.32
5.07
2.19
6.32
4.55
4.77
1.05
1.99
0.88
0.68
5.11
1.25
4.22
0.68
3.15
4.78
1.30
2.46
0.30
4.32
5.07
2.19
1.34
1.10
3.01
4.96
2.52
0.60
2.01
2.81
2.49
0.80
0.09
2.02
6.16
1.96
0.56
0.77
2.87
6.13
2.39
1.37
0.62
2.14
6.11
3.69
2.62
1.84
Chondroitin-
6-sulphate
0.08
1.16
0.20
0.21
0.00
0.70
1.30
0.25
0.49
0.00
0.13
0.18
0.23
0.07
0.07
0.00
1.00
0.17
0.14
0.34
0.08
1.16
0.20
0.21
0.09
1.30
0.25
0.49
0.00
0.20
0.66
0.12
0.05
0.00
0.18
1.50
0.20
0.00
0.05
0.54
0.24
0.36
0.00
0.00
0.13
0.09
0.55
0.00
0.10
0.02
0.00
0.30
0.00
0.298
0.380
Dermatan
0.10
0.11
0.00
0.00
0.00
0.19
0.38
0.00
0.37
0.00
0.00
0.00
0.00
0.00
0.00
0.09
0.11
0.00
0.00
0.00
0.10
0.11
0.00
0.00
0.00
0.38
0.00
0.37
0.00
0.11
0.27
0.29
0.00
0.00
0.20
0.22
0.00
0.00
0.22
0.19
0.00
0.00
0.00
0.22
0.05
0.00
0.26
0.00
0.15
0.15
0.00
0.54
0.00
0.098
0.134
Dermatan-
4-sulphate
0.51
0.61
1.61
1.15
0.83
0.52
0.94
1.90
1.26
0.63
0.00
0.00
0.00
0.00
0.00
0.82
0.89
1.27
1.42
0.86
0.51
0.61
1.61
1.15
0.83
0.94
1.90
1.26
0.63
0.70
0.72
0.72
1.28
1.39
1.07
0.86
1.34
0.73
0.67
0.75
1.33
1.18
0.89
1.06
0.70
1.39
1.51
0.79
0.86
0.90
1.10
1.54
0.67
0.921
0.453
Dermatan-
6-sulphate
0.00
0.00
0.02
0.22
0.00
0.00
0.09
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.02
0.00
0.00
0.02
0.22
0.00
0.09
0.00
0.00
0.00
0.00
0.00
0.01
0.00
0.00
0.00
0.00
0.01
0.00
0.00
0.07
0.00
0.00
0.00
0.00
0.00
0.18
0.21
0.00
0.01
0.00
0.00
0.12
0.00
0.024
0.058
Sum
6.90
8.58
12.24
4.44
8.10
10.75
10.69
11.96
14.56
6.61
10.83
8.98
8.90
2.63
4.04
10.39
8.19
11.99
6.34
13.96
6.90
8.58
12.24
4.44
8.19
10.69
11.96
14.56
6.61
11.71
9.81
7.64
13.44
8.63
6.03
10.58
8.46
6.66
5.47
7.32
4.97
17.94
5.38
6.28
7.64
11.63
19.92
7.33
12.42
5.18
5.51
20.55
8.49
9.33
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Our data showed significant differences (p < 0.005,
Wilcoxon test for pair differences) between the main
glycosaminoglycan disaccharide values in men and
women. There was no detectable age-dependency, but
subjects younger than 18 and older than 60 were not
included in the study.
b) females (n = 55)
Glycosaminoglycan disaccharides [μιηοΐ/ΐ]
Patients
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
X
s
Hyaluronan
0.46
0.44
0.00
0.08
1.03
1.48
0.47
0.04
0.07
0.80
0.00
0.10
0.06
0.00
0.00
0.24
0.40
0.20
0.00
0.52
0.46
0.44
0.00
0.08
1.03
1.48
0.47
0.04
0.07
0.80
0.40
0.36
0.18
0.00
0.00
0.00
0.55
0.17
0.07
0.35
0.38
0.78
0.00
0.15
1.05
0.48
0.25
0.07
0.00
0.61
0.26
0.36
0.27
0.00
0.60
0.338
0.364
Chondroitin
12.43
8.46
12.83
7.15
7.73
12.26
10.14
13.53
9.80
9.84
4.51
3.73
4.58
1.42
3.97
9.68
10.23
12.50
10.28
7.43
12.43
8.46
12.83
7.15
7.73
12.26
10.14
13.53
9.80
9.84
11.26
11.32
13.26
5.97
11.37
10.34
10.11
14.65
10.50
7.90
14.05
10.75
3.40
6.30
9.03
14.34
8.10
8.68
12.24
11.25
14.64
5.90
8.32
6.26
9.80
9.52
3.09
Chondroitin-
4-suLphate
3.42
1.78
11.39
7.85
2.56
2.65
1.73
8.61
9.42
3.10
7.35
2.67
3.90
1.35
5.02
2.42
2.10
12.70
11.08
2.64
3.42
1.78
11.39
7.85
2.56
2.65
1.73
8.61
9.42
3.10
2.56
3.26
11.79
7.24
4.66
3.78
5.22
14.93
8.78
1.71
4.21
4.43
3.95
3.12
3.19
4.30
2.72
9.98
10.68
2.40
3.65
1.83
10.20
8.23
4.84
5.42
3.53
Chondroitin-
6-sulphate
0.73
0.42
0.10
0.00
0.04
0.41
0.49
0.04
0.26
0.10
0.24
0.02
0.03
0.06
0.10
0.36
0.40
0.00
0.24
0.19
0.73
0.42
0.10
0.00
0.04
0.41
0.49
0.04
0.26
0.10
0.29
0.51
0.16
0.09
0.16
0.48
0.77
0.00
0.29
0.02
0.28
0.55
0.00
0.00
0.16
0.48
0.34
0.00
0.07
0.10
0.61
0.26
0.28
0.09
0.10
0.235
0.211
Dermatan
0.00
0.00
0.00
0.00
0.16
0.00
0.00
0.00
0.13
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.09
0.00
0.00
0.00
0.00
0.00
0.16
0.00
0.00
0.00
0.13
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.05
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.37
0.00
0.00
0.00
0.16
0.00
0.00
0.023
0.065
Derma tan -
4-sulphate
0.25
0.00
1.29
1.12
1.38
0.00
0.38
1.06
0.86
1.31
0.00
0.00
0.00
0.00
0.00
0.00
0.00
1.38
1.33
0.85
0.25
0.00
1.29
1.12
1.38
0.00
0.38
1.06
0.86
1.31
0.17
0.43
1.30
1.06
1.17
0.00
0.28
1.33
1.16
1.19
0.00
0.41
1.31
0.95
1.36
0.36
0.27
1.22
1.28
1.22
0.00
0.00
1.10
1.37
0.95
0.705
0.552
Dermatan-
6-sulphate
0.00
0.00
0.00
0.10
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.10
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.05
0.09
0.10
0.00
0.00
0.00
0.00
0.08
0.00
0.00
0.00
0.10
0.08
0.00
0.00
0.16
0.17
0.21
0.023
0.049
Sum
17.29
11.10
25.61
16.30
12.90
16.80
13.21
23.28
20.54
15.15
12.10
6.52
8.57
2.83
9.09
12.70
13.13
26.78
23.02
11.63
17.29
11.10
25.61
16.30
12.90
16.80
13.21
23.28
20.54
15.15
14.68
15.88
26.69
14.36
17.36
14.60
16.93
31.18
20.89
11.27
18.92
16.92
8.66
10.52
14.87
19.96
11.68
19.95
24.74
15.66
19.16
8.35
20.49
16.12
16.50
16.31
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Dermatan-4-sulphate disaccharides were found in
concentrations up to 0.81 μπιοΐ/ΐ serum. Dupuoy et
al. (16) determined 0 to 2 mg/1 for the reference value
of polymeric dermatan sulphate in human plasma.
The principle of the assay is the measurement of
residual amidolytic thrombin activity after incubation
with heparin cofactor II in defibrinated plasma; der-
matan sulphate accelerates thrombin inhibition by
heparin cofactor.
For hyaluronan the reference value has been reported
between 10 and 100 μg/l serum (17,18). In the present
study, the mean serum concentrations of hyaluronan
disaccharides were 0.26 μηιοΐ/ΐ (men) and 0.34 μπιοΐ/ΐ
(women).
When these results are converted from μηιοί disac-
charides into μ§ polymeric glycosaminoglycans, they
are in accordance with the reference values.
Serum was preferred, although plasma could also be
used (19, 20). In practice, the isolation of glycosami-
noglycans from serum was shorter and less demand-
ing. With both methods the isolation of glycosami-
noglycans was quantitative.
Total glycosaminoglycan concentrations show good
agreement with the results of Larking (2) and Strapans
et al. (5).
Conclusions
The presented method quantifies glycosaminoglycans
in human serum or plasma as disaccharides. Applying
this high specific and sensitivefmethod, quantitative
results can be obtained with good precision, accuracy
and performance. This HPLC method can therefore
be considered as a candidate reference method. Fur-
thermore, it allows the detection of the distribution
patterns of the glycosaminoglycans, thereby providing
a useful tool for elucidating aspects of the biosynthesis
and degradation of proteoglycans.
Changes of plasma/serum glycosaminoglycan concen-
trations have been demonstrated in physiological and
pathological conditions (11 — 13). Therefore in clinical
practice the method could lead to a better understand-
ing of glycosaminoglycan involvement in disease.
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